Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
METSERA Aktie jetzt für 0€ handeln | |||||
14.08. | SoftBank adds new Metsera, eToro stakes, pares Lemonade holding, among Q2 trades | 50 | Seeking Alpha | ||
29.07. | Cantor Fitzgerald bekräftigt positives Votum für Metsera vor wichtigen Studiendaten | 5 | Investing.com Deutsch | ||
29.07. | Metsera stock rating reiterated by Cantor Fitzgerald ahead of key updates | 4 | Investing.com | ||
28.07. | Metsera, Inc. Loss At -$68.72 Mln In Q2 | 2 | RTTNews | ||
28.07. | Metsera, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
28.07. | Metsera, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
28.07. | Metsera, Inc.: Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress | 341 | GlobeNewswire (Europe) | MET-097i (fully biased once-monthly GLP-1 RA) VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog)... ► Artikel lesen | |
20.06. | Metsera stock initiated at overweight by Wells Fargo on obesity drug | 6 | Investing.com | ||
13.06. | Cantor Fitzgerald reiterates Metsera stock rating on strong MET-233i results | 5 | Investing.com | ||
12.06. | Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results | 2 | Insider Monkey | ||
10.06. | Metsera extends gains after early-stage trial data for obesity therapy | 3 | Seeking Alpha | ||
09.06. | Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data | 1 | Benzinga.com | ||
09.06. | Metsera's Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med | 1 | MedCity News | ||
09.06. | Metsera shares climb on early data for amylin-targeting obesity shot | 1 | BioPharma Dive | ||
09.06. | Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch | 2 | Investor's Business Daily | ||
09.06. | Metsera shares soar on positive amylin candidate trial results | 2 | Investing.com | ||
09.06. | Metsera posts weight loss data for amylin analog, teeing up monthly GLP-1 combo plans | 2 | FierceBiotech | ||
09.06. | Metsera reports promising Phase 1 trial results for obesity treatment | 5 | Investing.com | ||
09.06. | Metsera, Inc.: Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i | 1.204 | GlobeNewswire (Europe) | Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated... ► Artikel lesen | |
09.06. | Metsera, Inc. - 8-K, Current Report | 4 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 28,060 | +0,48 % | Bayer: Endlich Licht am Ende des Tunnels? Die nächsten Kursziele | Die Bayer-Aktie befindet sich in einer wichtigen und womöglich auch richtungsweisenden Phase. Sieht sie nach der schier endlosen Korrektur endlich Licht am Ende des Tunnels? Sowohl unter fundamentalen... ► Artikel lesen | |
PFIZER | 21,150 | -0,02 % | BioNTech SE: Pfizer and BioNTech's COMIRNATY Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 | The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1Shipping of the LP.8.1-adapted vaccine will... ► Artikel lesen | |
GILEAD SCIENCES | 96,04 | -0,57 % | EU Approves Gilead's Twice-Yearly Lenacapavir For HIV Prevention | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) Tuesday said that the European Commission has granted marketing authorization for lenacapavir for pre-exposure prophylaxis to reduce the... ► Artikel lesen | |
AURORA CANNABIS | 4,600 | 0,00 % | Unglaubliche Prognose für Montag setzt Aurora Cannabis Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
ABBVIE | 179,60 | -0,22 % | AbbVie's RINVOQ Secures Health Canada's Approval For Giant Cell Arteritis Treatment | WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV), Wednesday announced Health Canada has issued a Notice of Compliance for RINVOQ for the treatment of adults with giant cell arteritis, both used in... ► Artikel lesen | |
CANOPY GROWTH | 1,520 | -0,39 % | Aktien-Trading 4 Dummies - 3 Aktien. 2 Experten. 0 Langeweile (Apple, Canopy Growth & Alcon) | ||
ELI LILLY | 625,90 | -0,03 % | Novo Nordisk: Aktie wieder auf dem absteigenden Ast - Eli Lilly legt nach | Das Rennen um die beste Abnehmpille ist längst eröffnet. Und einmal mehr bietet sich das Top-Duo im aufstrebenden Adipositas-Markt die Stirn: Eli Lilly und Novo Nordisk. Während die Dänen ihre Abnehmspritze... ► Artikel lesen | |
ASTRAZENECA | 136,30 | -0,44 % | DEUTSCHE BANK RESEARCH stuft ASTRAZENECA auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca mit einem Kursziel von 11000 Pence auf "Hold" belassen. Dies schrieb Analyst Emmanuel Papadakis in seiner am... ► Artikel lesen | |
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
TILRAY BRANDS | 1,181 | -0,51 % | Kursziel 2 US-Dollar: Trumps Cannabis-Kurswechsel: Tilray-Aktie im Kursrausch | © Foto: Bebeto Matthews - APDie Cannabis-Branche in den USA steht vor einem möglichen Richtungswechsel - und Tilray könnte der große Profiteur sein. Das Analysehaus Jefferies hebt sein Kursziel an,... ► Artikel lesen | |
BRISTOL-MYERS SQUIBB | 40,245 | -0,26 % | Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025 | Findings from COLLIGO-HCM reinforce Camzyos' efficacy and safety profile in reducing left ventricular outflow tract (LVOT) obstruction and improving symptom burden in a racially diverse, global... ► Artikel lesen | |
TEVA | 15,800 | +0,32 % | Neues Abnehmmittel kommt!: Vorsicht Novo Nordisk & Eli Lilly - Teva bringt "Abnehm-Generika" auf US-Markt! | Novo Nordisk und Eli Lilly bekommen Konkurrenz: Teva steigt mit einem Generikum in den US-Markt für Abnehmpräparate ein. Mit der FDA-Zulassung steigt der israelische Pharmariese in den milliardenschweren... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 334,20 | -0,06 % | Maze Therapeutics referred to federal marketing regulators over challenge brought by Vertex | ||
ABBOTT LABORATORIES | 113,22 | -0,19 % | Abbott Gets CE Mark For Expanded Indication For Navitor TAVI System | NORTH CHICAGO (dpa-AFX) - Abbott (ABT) has received CE Mark in Europe for an expanded indication for the Navitor transcatheter aortic valve implantation system to treat people with symptomatic... ► Artikel lesen | |
TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | CSE Bulletin: Suspensions - Blender Bites Limited, TAAT Global Alternatives Inc. | Toronto, Ontario--(Newsfile Corp. - Le 16 mai/May 2025) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as... ► Artikel lesen |